AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension.
In the trial, patients who received either 1 mg or 2 mg of baxdrostat once daily had a greater reduction in mean seated systolic blood pressure after 12 weeks compared with those who received a placebo, according to a July 14 news release from the drugmaker.
Participants continued their existing antihypertensive treatments during the study, the release said.
AstraZeneca said it will share data with regulators and present results from the study at the European Society of Cardiology Congress in August.